Trial Profile

A Phase 2 Pilot Study of ADP-A2M4 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 17 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afamitresgene autoleucel (Primary) ; Pembrolizumab (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms SPEARHEAD 2
Sponsors Adaptimmune

Most Recent Events

08 Nov 2021 Planned End Date changed from 1 Oct 2036 to 1 Dec 2021.
08 Nov 2021 Planned primary completion date changed from 1 Apr 2022 to 1 Dec 2021.
04 Nov 2021 According to an Adaptimmune media release, the company has now closed to enrollment in this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com